Status:
COMPLETED
Correlations Between Wireless pH Monitoring and Variation in Reflux Symptom Questionnaire, 7 Day Recall
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
18+ years
Brief Summary
The diagnosis of gastro-oesophageal reflux disease (GORD) is often based on 24-hour catheter-based pH studies. The Bravo™ wireless pH monitoring revolutionised the study of GORD, allowing patients an ...
Detailed Description
This is prospective, observational study on patients with gastro-oesophageal reflux symptoms referred for wireless 96-hour pH (potential of hydrogen) monitoring for clinical indications. The principal...
Eligibility Criteria
Inclusion
- Males and non-pregnant females over the age of 18 years.
- Gastro-oesophageal symptoms in accordance with Montreal criteria#
- Patients with clinical indications for Bravo™, including:
- symptomatic patients with non-diagnostic endoscopy and catheter-based pH tests
- preoperative evaluation before antireflux procedures
- persistent or recurrent post-operative symptoms
- Participants need to understand spoken and written English
- Patients must sign an informed consent form.
Exclusion
- Contraindications to endoscopy
- Known allergy or intolerance to PPI
- History of bleeding diathesis or coagulopathy
- Chronic liver disease, oesophageal varices
- Pregnancy
- Any medical or non-medical condition that in the opinion of the research team will make the candidate unfit for this study, such as heart failure and drug abuse.
Key Trial Info
Start Date :
March 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 19 2019
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT03407456
Start Date
March 20 2018
End Date
August 19 2019
Last Update
August 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom, SE1 7EH